Project Grant R01HL174912
Award Date 9/17/25
Completion Date 7/31/30
Dollars Obligated $710K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to evaluate factors driving delays in the diagnosis of peripartum cardiomyopathy (PPCM), a form of heart failure that occurs in the weeks or months after childbirth. The $601,075 award will fund a mixed-methods study to determine patient-reported, provider, and health system factors contributing to delayed PPCM diagnosis, with a focus on understanding...
- The federal Project Grant award titled "CARDIAC EFFECTS OF MINERALOCORTICOID RECEPTOR ANTAGONISM AFTER PREECLAMPSIA (CARDAMOM)" was awarded by the National Heart, Lung, and Blood Institute (CFDA #93.837 Cardiovascular Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital, for $658,418.00. The award aims to conduct a randomized, double-blind clinical study investigating whether mineralocorticoid receptor blockade can promote favorable...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $1,127,798 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). This 7-year grant, effective February 1, 2025, will support research to understand the role of macrophages in preserving cardiovascular health, illuminating their contributions to cardiovascular disease, and...
- The Project Grant award of $759,658 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and validate a mechanomicroscopy imaging platform for the transbronchial assessment of pulmonary artery pressure and arterial smooth muscle thickening in patients with pulmonary hypertension due to lung disease. The key products and services to be...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,559,308 to examine the impact of severe pre-eclampsia on heart function in diverse racial groups of women. The project will evaluate heart function at delivery and at 6- and 12-months postpartum, as well as characterize the cardiomyopathic genetic profile of the participants. A sub-award of undisclosed amount has been issued to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $125,250 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 2-year research study on the role of the cytokine FAM3D in heart failure. The principal investigator, Dr. James Rhee, will lead a team of scientists to investigate how FAM3D regulates cardiac fibroblasts and the lymphatic system to limit inflammation and...
- This $247,500 project grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to develop a non-invasive model for early detection of pulmonary vascular dysfunction (PVD) in patients with acute respiratory distress syndrome (ARDS). The research aims to leverage proteomic analysis of plasma samples from ARDS patient cohorts to derive and validate a classifier that can accurately identify PVD, a high-risk ARDS subgroup with...
- This $165,353 Project Grant was awarded on September 25, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant funding will support research to define the association between severe obesity and regional lung perfusion, as well as test the effect of severe obesity on pulmonary vasoreactivity in patients with acute hypoxemic respiratory failure....
- The National Heart, Lung, and Blood Institute awarded a $171,488 project grant to The Children's Hospital Corporation (doing business as Boston Children's Hospital) under the Cardiovascular Diseases Research program (CFDA 93.837). The project aims to investigate the role of the protein CMYA5 in regulating the activity of the ryanodine receptor 2 (RYR2) in cardiomyocytes. Specifically, the research will examine how CMYA5 binds to and inhibits RYR2, which is involved in calcium signaling and...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,674 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to build the largest echocardiography registry in the world and apply advanced causal inference methods to measure the effects of guideline-directed medical therapies on mortality in patients with heart failure and mid-range ejection...